{
  "guideline": {
    "id": "PA166182846",
    "name": "Annotation of DPWG Guideline for efavirenz and CYP2B6",
    "source": "DPWG",
    "version": 11,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182846",
    "relatedChemicals": [
      {
        "id": "PA449441",
        "name": "efavirenz",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA123",
        "name": "cytochrome P450 family 2 subfamily B member 6",
        "symbol": "CYP2B6"
      }
    ],
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451448321,
            "_label": "*1",
            "function": {
              "term": "Normal function",
              "termId": "haplotypeTags:1445558335"
            }
          },
          {
            "id": 1451695662,
            "_label": "*5",
            "function": {
              "term": "Substrate dependent",
              "termId": "alleleFunction:1451695661"
            }
          },
          {
            "id": 1451697820,
            "_label": "*6",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451697842,
            "_label": "*7",
            "function": {
              "term": "Decreased function (*7)",
              "termId": "alleleFunction:1451697841"
            }
          },
          {
            "id": 1451697822,
            "_label": "*18",
            "function": {
              "term": "No function",
              "termId": "haplotypeTags:1445558515"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA520",
            "name": "chr19",
            "symbol": null
          },
          "strand": "plus",
          "id": "PA123",
          "name": "cytochrome P450 family 2 subfamily B member 6",
          "symbol": "CYP2B6"
        }
      }
    ]
  },
  "annotationGroups": [
    {
      "id": "PA166244501",
      "name": "NM",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2B6:Normal function/Normal function"
      ],
      "metabolizerStatus": {
        "id": 1451448447,
        "html": "<p>Normal Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451448448,
        "html": "<p>The guideline does not provide a recommendation for efavirenz in normal metabolizers.</p>\n"
      },
      "implications": {
        "id": 1451448446,
        "html": "<p>The guideline does not provide a description of the impact of a normal metabolizer phenotype on efavirenz.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244481",
      "name": "IM",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Possibly",
        "termId": "rxChange:1448602496"
      },
      "genePhenotypes": [
        "CYP2B6:Decreased function (*7)/Normal function",
        "CYP2B6:Decreased function/Normal function",
        "CYP2B6:No function/Normal function"
      ],
      "metabolizerStatus": {
        "id": 1451838374,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838375,
        "html": "<p>Determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed. In 14 IM adults, a dose reduction to 400 mg/day (2/3rd of the standard dose) was sufficient to achieve therapeutic plasma concentrations and to reduce or resolve side effects. The therapeutic range established for efavirenz is 1000-4000 ng/ml.</p>\n"
      },
      "implications": {
        "id": 1451838373,
        "html": "<p>Genetic variations increase the efavirenz plasma concentration and therefore the risk of side effects. However, the efavirenz plasma concentration remains within the therapeutic range for the majority of patients.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244482",
      "name": "PM",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2B6:Decreased function (*7)/Decreased function (*7)",
        "CYP2B6:Decreased function (*7)/No function",
        "CYP2B6:Decreased function/Decreased function",
        "CYP2B6:Decreased function/Decreased function (*7)",
        "CYP2B6:Decreased function/No function",
        "CYP2B6:No function/No function"
      ],
      "metabolizerStatus": {
        "id": 1451838377,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838378,
        "html": "<p>Efavirenz in MONOpreparation, adults and children FROM 40 KG: Body mass index LESS THAN or EQUAL to 25: 1. The recommended initial dose is 400 mg/day and this dose should be titrated to plasma concentration if needed (further reduction to 200 mg/day or in rare cases an increase to 600 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml. Body mass index GREATER than 25: 1. The recommended initial dose is 600 mg/day and this dose should be titrated to plasma concentration if needed (reduction to 400 or 200 mg/day). The therapeutic range established for efavirenz is 1000-4000 ng/ml.\n*Efavirenz in MONOpreparation, children LIGHTER THAN 40 KG: 1. Start with the standard dose and titrate this dose to plasma concentration if needed. In adults, therapeutic plasma concentrations were achieved at either 2/3rd of the standard dose (1/3rd of the patients) or 1/3rd of the standard dose (2/3rd of the patients). In children younger than 3 years, therapeutic plasma concentrations were achieved at doses of approximately 10 mg/kg per day (as capsules) (100 mg/day for 7-14 kg and 150 mg/day for 14-17 kg; 50-75% of the standard dose). The therapeutic range established for efavirenz is 1000-4000 ng/ml.\n*Efavirenz in COMBINATION preparation: 1. Initiate the combination preparation and titrate the efavirenz dose to plasma concentration if needed (reduction to 400 or 200 mg/day) The therapeutic range established for efavirenz is 1000-4000 ng/ml.</p>\n"
      },
      "implications": {
        "id": 1451838376,
        "html": "<p>Genetic variations increase the risk of side effects. The standard dose leads to an efavirenz concentration in the toxic range in the majority of patients with this genotype.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166264861",
      "name": "*1/*5 or *5/*5",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2B6:Normal function/Substrate dependent",
        "CYP2B6:Substrate dependent/Substrate dependent"
      ],
      "metabolizerStatus": {
        "id": 1451872345,
        "html": "<p>Normal Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451872346,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": {
        "id": 1451872344,
        "html": "<p>Gene variant *5 has no effect on the metabolism and consequently on the efficacy and side effects of efavirenz.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166265181",
      "name": "*5/*6 or *5/*18",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Possibly",
        "termId": "rxChange:1448602496"
      },
      "genePhenotypes": [
        "CYP2B6:Decreased function/Substrate dependent",
        "CYP2B6:No function/Substrate dependent"
      ],
      "metabolizerStatus": {
        "id": 1451872324,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451872325,
        "html": "<p>Determine the efavirenz plasma concentration if side effects occur and reduce the dose if needed. In 14 adults with a genotype with the same effect, a reduction of the dose to 400 mg/day (2/3 of the standard dose) was sufficient to achieve therapeutic plasma concentrations and for the side effects to reduce or disappear. The therapeutic range established for efavirenz is 1000-4000 ng/mL.</p>\n"
      },
      "implications": {
        "id": 1451872323,
        "html": "<p>The genetic variation increases the plasma concentration of efavirenz and thereby the risk of side effects. However, the efavirenz plasma concentration remains within the therapeutic range for the majority of patients.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166265182",
      "name": "*5/*7",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2B6:Decreased function (*7)/Substrate dependent"
      ],
      "metabolizerStatus": {
        "id": 1451872341,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451872343,
        "html": "<p>The guideline does not provide a recommendation for efavirenz in patients with the *5/*7 genotype.</p>\n"
      },
      "implications": {
        "id": 1451872340,
        "html": "<p>The guideline does not provide a description of the impact of the *5/*7 genotype on efavirenz.</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": [],
  "version": "2023-02-05-00-25"
}